Published June 8, 2023 | Published
Journal Article Open

Copper-catalysed enantioconvergent alkylation of oxygen nucleophiles

  • 1. ROR icon California Institute of Technology

Abstract

Because carbon–oxygen bonds are commonplace in organic molecules, including chiral bioactive compounds, the development of new methods for their construction with simultaneous control of stereoselectivity is an important objective in synthesis. The Williamson ether synthesis, first reported in 1850 (1), is the most widely used approach to the alkylation of an oxygen nucleophile, but it has significant limitations (scope and stereochemistry) due to its reaction mechanism (SN2 pathway). Transition-metal catalysis of the coupling of an oxygen nucleophile with an alkyl electrophile has the potential to address these limitations, but progress to date has been very limited (27), especially with regard to controlling enantioselectivity. Herein we establish that a readily available copper catalyst can achieve an array of enantioconvergent substitution reactions of α-haloamides, a useful family of electrophiles, by oxygen nucleophiles; the reaction proceeds under mild conditions in the presence of a wide variety of functional groups. The catalyst is uniquely effective in being able to achieve enantioconvergent alkylations not only of oxygen nucleophiles, but also of nitrogen nucleophiles, furnishing support for the potential of transition-metal catalysts to provide a solution to the pivotal challenge of achieving enantioselective alkylations of heteroatom nucleophiles.

Copyright and License

© The Author(s), under exclusive licence to Springer Nature Limited 2023. 

Acknowledgement

Support has been provided by the National Institutes of Health (National Institute of General Medical Sciences, R01–GM109194 and R35–GM145315), the Beckman Institute (support for the Caltech Center for Catalysis and Chemical Synthesis, EPR Facility and X-ray Crystallography Facility), the Dow Next-Generation Educator Fund (grant to Caltech) and Boehringer–Ingelheim Pharmaceuticals. We thank R. Anderson, H. Cho, S. Munoz, P. H. Oyala, F. Schneck, M. K. Takase and X. Tong for assistance and discussions.

Contributions

C.C. performed all experiments. C.C. and G.C.F. wrote the paper. Both authors contributed to the analysis and the interpretation of the results. 

Data Availability

The data that support the findings of this study are available within the paper, its Supplementary Information (experimental procedures and characterization data), and from the Cambridge Crystallographic Data Centre (https://www.ccdc.cam.ac.uk/structures; crystallographic data are available free of charge under CCDC reference numbers CCDC 2192280–2192286).

Conflict of Interest

The authors declare no competing interests.

Files

nihms-1973415.pdf
Files (36.9 MB)
Name Size Download all
md5:d06b6cecb684f09deefbc799f970840d
34.5 MB Preview Download
md5:2ed8150397ef9435c6c6e298cf317a45
2.4 MB Preview Download

Additional details

Created:
June 3, 2024
Modified:
June 3, 2024